Independent Franchise Partners Llp Boosted Johnson & Johnson (JNJ) Stake; Merit Medical Systems Has 1.21 Sentiment

Merit Medical Systems, Inc. (NASDAQ:MMSI) Logo

Merit Medical Systems Inc (MMSI) investors sentiment increased to 1.21 in Q3 2018. It’s up 0.08, from 1.13 in 2018Q2. The ratio increased, as 105 investment professionals opened new or increased equity positions, while 87 cut down and sold their stock positions in Merit Medical Systems Inc. The investment professionals in our database now hold: 49.85 million shares, up from 45.77 million shares in 2018Q2. Also, the number of investment professionals holding Merit Medical Systems Inc in top ten equity positions increased from 3 to 4 for an increase of 1. Sold All: 11 Reduced: 76 Increased: 72 New Position: 33.

Independent Franchise Partners Llp increased Johnson & Johnson (JNJ) stake by 28.35% reported in 2018Q3 SEC filing. Independent Franchise Partners Llp acquired 1.93M shares as Johnson & Johnson (JNJ)’s stock rose 5.87%. The Independent Franchise Partners Llp holds 8.75M shares with $1.21B value, up from 6.81M last quarter. Johnson & Johnson now has $359.58 billion valuation. The stock decreased 0.06% or $0.09 during the last trading session, reaching $134.07. About 3.88 million shares traded. Johnson & Johnson (NYSE:JNJ) has risen 3.75% since February 13, 2018 and is uptrending. It has outperformed by 3.75% the S&P500. Some Historical JNJ News: 30/05/2018 – $SAN.FR, JNJ, MRK: Trump: In two weeks, big drug companies are going to announce a “voluntary, massive” drop in prices – ! $SAN.FR $JNJ $MRK; 26/04/2018 – FUJIREBIO SAYS ENTERED INTO AGREEMENT WITH JANSSEN PHARMACEUTICALS TO DEVELOP & COMMERCIALIZE AMYLOID; 17/04/2018 – Johnson & Johnson Sees About $600M-$800M Annual Pretax Cost Savings by 2022; 16/05/2018 – Johnson & Johnson to relaunch baby care line after its 20% sales decline; 01/05/2018 – Johnson & Johnson Vision Presents New Studies Revealing Antioxidant Properties of Ultraviolet Blocker in ACUVUE® Brand Contact; 03/05/2018 – Protagonist Therapeutics Announces Oral Presentation Accepted for Digestive Diseases Week Conference; 17/04/2018 – J&J – EXPECTS SUPPLY CHAIN ACTIONS WILL INCLUDE EXPANDING USE OF STRATEGIC COLLABORATIONS; 17/04/2018 – J&J PLANS TO IMPLEMENT ACTIONS ACROSS GLOBAL SUPPLY CHAIN; 02/04/2018 – April 9th Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit; 29/05/2018 – Novo Nordisk’s experimental diabetes pill proved better at lowering blood sugar levels than Eli Lilly and Boehringer Ingelheim’s established Jardiance

More notable recent Johnson & Johnson (NYSE:JNJ) news were published by: Seekingalpha.com which released: “Johnson & Johnson to acquire Auris Health for $3.4B – Seeking Alpha” on February 13, 2019, also Seekingalpha.com with their article: “Johnson & Johnson: P/E Matters – Seeking Alpha” published on January 17, 2019, Benzinga.com published: “Johnson & Johnson Wins FDA Panel Backing For Nasal Spray Depression Drug; PDUFA Date Awaits (NYSE:JNJ) – Benzinga” on February 13, 2019. More interesting news about Johnson & Johnson (NYSE:JNJ) were released by: Seekingalpha.com and their article: “JNJ up 1% premarket on strong Q4 – Seeking Alpha” published on January 22, 2019 as well as Seekingalpha.com‘s news article titled: “JNJ’s TECNIS Eyhance IOL available in Europe – Seeking Alpha” with publication date: February 04, 2019.

Among 5 analysts covering Johnson \u0026 Johnson (NYSE:JNJ), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Johnson \u0026 Johnson had 7 analyst reports since October 11, 2018 according to SRatingsIntel. The stock of Johnson & Johnson (NYSE:JNJ) earned “Equal-Weight” rating by Morgan Stanley on Wednesday, January 2. On Wednesday, October 17 the stock rating was maintained by Credit Suisse with “Outperform”. On Wednesday, January 2 the stock rating was maintained by Citigroup with “Neutral”. The firm has “Neutral” rating by Citigroup given on Monday, October 22. The firm has “Outperform” rating by Wells Fargo given on Monday, January 14. Raymond James maintained the stock with “Outperform” rating in Wednesday, October 17 report. Morgan Stanley maintained the shares of JNJ in report on Thursday, October 11 with “Equal-Weight” rating.

Investors sentiment increased to 1.05 in Q3 2018. Its up 0.08, from 0.97 in 2018Q2. It improved, as 43 investors sold JNJ shares while 748 reduced holdings. 115 funds opened positions while 719 raised stakes. 1.70 billion shares or 7.91% less from 1.84 billion shares in 2018Q2 were reported. Independent Investors holds 4.29% or 88,149 shares. Community Fincl Services owns 25,657 shares. Voya Inv Mngmt Lc holds 1.12% of its portfolio in Johnson & Johnson (NYSE:JNJ) for 3.94 million shares. Jnba Financial Advisors reported 37,249 shares. 191,309 are owned by Cadinha And Co Ltd Com. Fund Evaluation Grp Lc holds 0.23% in Johnson & Johnson (NYSE:JNJ) or 9,862 shares. Telos Capital Mgmt has 1.11% invested in Johnson & Johnson (NYSE:JNJ) for 25,069 shares. Mitsubishi Ufj invested in 590 shares. Parametrica Management has 3,202 shares. Rockland has 2.49% invested in Johnson & Johnson (NYSE:JNJ). Guyasuta Investment Advsr accumulated 3.43% or 232,716 shares. Rothschild Cap Llc invested in 2,156 shares or 0.13% of the stock. 2,745 are held by Schaller Investment Grp. Prio Wealth Ltd Partnership, a Massachusetts-based fund reported 267,025 shares. Perigon Wealth Llc owns 39,797 shares.

Since August 27, 2018, it had 3 insider purchases, and 8 selling transactions for $79.44 million activity. $100,050 worth of stock was bought by MULCAHY ANNE M on Friday, December 14. Kapusta Ronald A also sold $1.23 million worth of Johnson & Johnson (NYSE:JNJ) shares. Shares for $133,910 were bought by PEREZ WILLIAM D. 166,695 shares were sold by Fasolo Peter, worth $24.41 million on Monday, December 3. 40,000 shares valued at $5.77M were sold by Duato Joaquin on Wednesday, November 7. 30,943 Johnson & Johnson (NYSE:JNJ) shares with value of $4.41 million were sold by Sneed Michael E. PRINCE CHARLES bought $268,731 worth of stock or 2,000 shares.

Analysts await Merit Medical Systems, Inc. (NASDAQ:MMSI) to report earnings on February, 27. They expect $0.45 earnings per share, up 36.36% or $0.12 from last year’s $0.33 per share. MMSI’s profit will be $24.68M for 32.12 P/E if the $0.45 EPS becomes a reality. After $0.47 actual earnings per share reported by Merit Medical Systems, Inc. for the previous quarter, Wall Street now forecasts -4.26% negative EPS growth.

Merit Medical Systems, Inc. designs, develops, makes, and markets medical products for interventional and diagnostic procedures worldwide. The company has market cap of $3.17 billion. The companyÂ’s Cardiovascular segment offers cardiology and radiology devices for diagnosing and treating coronary arterial, peripheral vascular, and other non-vascular diseases; and embolotherapeutic products. It has a 76.88 P/E ratio. It also provides vascular access products; guide wires, inflation devices, and diagnostic catheters for use in angiography procedures; therapeutic infusion systems and safety products; drainage catheters and drainage access products, support catheters, vascular retrieval devices, and dialysis access products; and embosphere microspheres and delivery systems, and microcatheters.

The stock decreased 0.09% or $0.05 during the last trading session, reaching $57.81. About 97,946 shares traded. Merit Medical Systems, Inc. (MMSI) has risen 33.77% since February 13, 2018 and is uptrending. It has outperformed by 33.77% the S&P500. Some Historical MMSI News: 02/05/2018 – MERIT MEDICAL ENTERS ALLIANCE & WORLDWIDE DISTRIBUTION WITH NIN; 30/04/2018 – Merit Medical Presenting at Bank of America Conference May 17; 19/03/2018 – merit medical systems, inc. | corvocet biopsy system | K180450 | 03/12/2018 |; 19/04/2018 – DJ Merit Medical Systems Inc, Inst Holders, 1Q 2018 (MMSI); 01/05/2018 – NinePoint Medical, Inc. Enters Into A Strategic Partnership and Worldwide Distribution with Merit Medical Systems, Inc; 10/04/2018 – Merit Medical at Deutsche Bank Health Care Conference May 9; 16/04/2018 – Merit Medical Closes Above 50-Day Moving Average: Technicals; 27/03/2018 – Merit Medical Presenting at Conference Tomorrow; 20/03/2018 – FDA: Merit Medical Systems, Inc.- Custom Dialysis Kit CF-4230 Without Gel, which includes Flex-Neck® Classic Peritoneal; 16/03/2018 Merit Medical Closes Below 50-Day Moving Average: Technicals

Since January 1, 0001, it had 0 buys, and 5 sales for $2.50 million activity.

More notable recent Merit Medical Systems, Inc. (NASDAQ:MMSI) news were published by: Nasdaq.com which released: “3 Reasons Growth Investors Will Love Merit Medical (MMSI) – Nasdaq” on January 21, 2019, also Nasdaq.com with their article: “Bet on These 5 Low Leverage Stocks to Escape Debt Traps – Nasdaq” published on February 06, 2019, Globenewswire.com published: “Detailed Research: Economic Perspectives on Inovalon, Merit Medical, Senseonics, Ocular Therapeutix, The Hartford Financial Services Group, and Synopsys — What Drives Growth in Today’s Competitive Landscape – GlobeNewswire” on January 22, 2019. More interesting news about Merit Medical Systems, Inc. (NASDAQ:MMSI) were released by: Nasdaq.com and their article: “Analysts Expect 19% Gains Ahead For SLYG – Nasdaq” published on January 15, 2019 as well as Nasdaq.com‘s news article titled: “Zacks.com featured highlights include: Merit Medical, Pinnacle West, Steelcase, Southwest and EMCOR – Nasdaq” with publication date: February 07, 2019.

Timpani Capital Management Llc holds 2.81% of its portfolio in Merit Medical Systems, Inc. for 158,973 shares. Aristotle Capital Boston Llc owns 423,476 shares or 1.91% of their US portfolio. Moreover, Eagle Boston Investment Management Inc has 1.9% invested in the company for 344,344 shares. The Massachusetts-based Redwood Investments Llc has invested 1.65% in the stock. Perceptive Advisors Llc, a New York-based fund reported 994,198 shares.

Merit Medical Systems, Inc. (NASDAQ:MMSI) Institutional Positions Chart